Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David M Kaye

Showing results (401-410 of 418) with videos related to

Pageof 42
Sort By:
Journal of the American College of Cardiology|September 1, 2017
Catheter Ablation Versus Medical Rate Control in Atrial Fibrillation and Systolic Dysfunction: The CAMERA-MRI StudySandeep Prabhu, Andrew J Taylor, Ben T Costello, et al.
Circulation|February 26, 2020
Deficiency of Prebiotic Fiber and Insufficient Signaling Through Gut Metabolite-Sensing Receptors Leads to Cardiovascular DiseaseDavid M Kaye, Waled A Shihata, Hamdi A Jama, et al.
Lancet (London, England)|February 5, 2022
Atrial shunt device for heart failure with preserved and mildly reduced ejection fraction (REDUCE LAP-HF II): a randomised, multicentre, blinded, sham-controlled trialSanjiv J Shah, Barry A Borlaug, Eugene S Chung, et al.
European Heart Journal|August 19, 2025
Withdrawal of heart failure therapy after atrial fibrillation rhythm control with ejection fraction normalization: the WITHDRAW-AF trialLouise Segan, Peter M Kistler, Shane Nanayakkara, et al.
Ebiomedicine|July 30, 2025
The association between circulating SIGLEC6 and preeclampsia: observational studies of seven cohortsTu'uhevaha J Kaitu'u-Lino, Teresa M MacDonald, Emerson Keenan, et al.
JACC. Heart Failure|June 27, 2024
2-Year Outcomes of an Atrial Shunt Device in HFpEF/HFmrEF: Results From REDUCE LAP-HF IIFinn Gustafsson, Mark C Petrie, Jan Komtebedde, et al.
Circulation Research|July 17, 2024
Maternal Diet and Gut Microbiota Influence Predisposition to Cardiovascular Disease in OffspringHamdi A Jama, Malathi S I Dona, Evany Dinakis, et al.
JAMA Cardiology|September 1, 2018
One-Year Safety and Clinical Outcomes of a Transcatheter Interatrial Shunt Device for the Treatment of Heart Failure With Preserved Ejection Fraction in the Reduce Elevated Left Atrial Pressure in Patients With Heart Failure (REDUCE LAP-HF I) Trial: A Randomized Clinical TrialSanjiv J Shah, Ted Feldman, Mark J Ricciardi, et al.
American Heart Journal|December 19, 2025
Corrigendum to "Long-term safety and outcomes after atrial shunting for heart failure with preserved or mildly reduced ejection fraction: 5-year and 3-year follow-up in the REDUCE LAP-HF I and II trials" [American Heart Journal (278)2024 Page Number:106-116]Sheldon E Litwin, Jan Komtebedde, Barry A Borlaug, et al.
European Heart Journal. Acute Cardiovascular Care|June 30, 2021
Pre-hospital heparin use for ST-elevation myocardial infarction is safe and improves angiographic outcomesJason E Bloom, Emily Andrew, Ziad Nehme, et al.
Pageof 42

Showing results (401-410 of 418) with videos related to

Sort By:
Pageof 42
Journal of the American College of Cardiology|September 1, 2017
Catheter Ablation Versus Medical Rate Control in Atrial Fibrillation and Systolic Dysfunction: The CAMERA-MRI StudySandeep Prabhu, Andrew J Taylor, Ben T Costello, et al.
Circulation|February 26, 2020
Deficiency of Prebiotic Fiber and Insufficient Signaling Through Gut Metabolite-Sensing Receptors Leads to Cardiovascular DiseaseDavid M Kaye, Waled A Shihata, Hamdi A Jama, et al.
Lancet (London, England)|February 5, 2022
Atrial shunt device for heart failure with preserved and mildly reduced ejection fraction (REDUCE LAP-HF II): a randomised, multicentre, blinded, sham-controlled trialSanjiv J Shah, Barry A Borlaug, Eugene S Chung, et al.
European Heart Journal|August 19, 2025
Withdrawal of heart failure therapy after atrial fibrillation rhythm control with ejection fraction normalization: the WITHDRAW-AF trialLouise Segan, Peter M Kistler, Shane Nanayakkara, et al.
Ebiomedicine|July 30, 2025
The association between circulating SIGLEC6 and preeclampsia: observational studies of seven cohortsTu'uhevaha J Kaitu'u-Lino, Teresa M MacDonald, Emerson Keenan, et al.
JACC. Heart Failure|June 27, 2024
2-Year Outcomes of an Atrial Shunt Device in HFpEF/HFmrEF: Results From REDUCE LAP-HF IIFinn Gustafsson, Mark C Petrie, Jan Komtebedde, et al.
Circulation Research|July 17, 2024
Maternal Diet and Gut Microbiota Influence Predisposition to Cardiovascular Disease in OffspringHamdi A Jama, Malathi S I Dona, Evany Dinakis, et al.
JAMA Cardiology|September 1, 2018
One-Year Safety and Clinical Outcomes of a Transcatheter Interatrial Shunt Device for the Treatment of Heart Failure With Preserved Ejection Fraction in the Reduce Elevated Left Atrial Pressure in Patients With Heart Failure (REDUCE LAP-HF I) Trial: A Randomized Clinical TrialSanjiv J Shah, Ted Feldman, Mark J Ricciardi, et al.
American Heart Journal|December 19, 2025
Corrigendum to "Long-term safety and outcomes after atrial shunting for heart failure with preserved or mildly reduced ejection fraction: 5-year and 3-year follow-up in the REDUCE LAP-HF I and II trials" [American Heart Journal (278)2024 Page Number:106-116]Sheldon E Litwin, Jan Komtebedde, Barry A Borlaug, et al.
European Heart Journal. Acute Cardiovascular Care|June 30, 2021
Pre-hospital heparin use for ST-elevation myocardial infarction is safe and improves angiographic outcomesJason E Bloom, Emily Andrew, Ziad Nehme, et al.
Pageof 42